NCT06365671View on ClinicalTrials.gov

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
B-cell Non Hodgkin Lymphoma
Interventions
OTHER

autologous stem-cell transplantation

high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)

DRUG

Relmacabtagene autoleucel (relma-cel)

relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER